Are you routinely offering nivolumab for second-line treatment of small cell lung cancer?
Based on recently published data from CheckMate 032, do you now offer nivolumab to small cell patients who have progressed after first-line chemotherapy? If so, do you consider giving ipilimumab in combination with nivo to fit patients?